Keywords: Sanofi-Aventis, Regeneron, Research collaboration, Licensing, Monoclonal antibodies
Sanofi-Aventis expands deal with Regeneron to $160 million pa to end 2017
Article | 11 November 2009
France’s Sanofi-Aventis and USA-based Regeneron Pharmaceutical have entered into an agreement to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies through 2017, which would cost the French drug major over $1 billion over the eight years to expand its foot-print in biotechnology.
Under the extended deal, Sanofi will increase its annual funding commitment from $100 million a year to $160 million beginning 2010 and has an option to extend the program for up to an additional three years. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
